Clinical trial
Alternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00000221 |
|---|---|
| Title | Alternate-Day Buprenorphine Administration. Phase I - 3 |
| Official title | Alternate-Day Buprenorphine Administration. Phase I |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | University of Vermont |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Opioid-Related Disorders |
| Intervention type | Drug |
| Interventions | Buprenorphine |
| Enrollment | 0 |
| Start date | Apr 1, 1992 |
| First posted | Sep 21, 1999 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: